EN 简 繁
img img img
QR


Who We Are

Sirnaomics is a clinical-stage RNA therapeutics biopharmaceutical company that is discovering and developing innovative drugs for indications with significant unmet medical needs in areas such as cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics. We are based in both the U.S. and China, having been founded in 2007 in Gaithersburg, Maryland.

Sirnaomics’ proprietary delivery platforms for RNA-based therapeutics are the foundation of our product pipeline. Our polypeptide nanoparticle delivery platform (PNP) is primarily used to administer mRNA vaccines and therapeutics. Our GalNAc delivery platform provides systemic administration for liver-targeting RNAi therapeutics.

Who We Are

Science & Pipeline

The Science of RNAi
Pipeline
Research & Development
Drug Delivery Systems
Clinical Studies
Manufacturing
Media
2022.08.29

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

2022.08.26

Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

2022.08.23

Sirnaomics' 2022 interim results presentation will be held on 31 August 2022

View More
Investor Relations
Announcements & Circulars
Announcements & Circulars
Stock Information
Stock Information
Email Subscription
Email Subscription
View More